| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 22,519 | 24,896* | 30,564 | NaN |
| Cost of revenues | 1,227 | 1,248* | 1,628 | NaN |
| Selling and marketing | 14,136 | 10,928* | 15,328 | NaN |
| Research and development | 6,738 | 6,609* | 2,363 | NaN |
| General and administrative | 7,220 | 7,847* | 4,319 | NaN |
| Loss on disposal of assets, net | NaN | -1* | -1 | NaN |
| Transaction costs | 2,553 | NaN | NaN | NaN |
| Total operating expenses | 31,874 | 26,632* | 23,639 | NaN |
| (gain) income from operations | -9,355 | -1,736* | 6,925 | NaN |
| Change in fair value of warrant liability | -89 | -2,776* | 23 | NaN |
| Interest income, net | NaN | 437* | NaN | NaN |
| Other income, net | 29 | -3,686* | 727 | NaN |
| (gain) income before income taxes | -9,237 | -2,209* | 7,629 | NaN |
| Provision for income taxes | 621 | -523* | 1,693 | NaN |
| Net (gain) income from operations | -9,858 | -1,686* | 5,936 | 1,576 |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent, total | NaN | NaN | NaN | 303 |
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | NaN | NaN | NaN | 1,879 |
| Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to noncontrolling interest | NaN | NaN | NaN | 104 |
| Less allocation of undistributed (gaines) earnings to noncontrolling interest | -1,167 | -337* | 2,326 | 1,134 |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | NaN | NaN | NaN | 1,238 |
| Comprehensive income (loss), net of tax, attributable to parent | NaN | NaN | NaN | 641 |
| Net (gain) income available to common stockholders | -8,691 | -1,349 | 3,610 | NaN |
| Basic EPS | -0.1 | -0.015 | 0.04 | 0 |
| Diluted EPS | -0.1 | -0.013 | 0.03 | 0 |
| Basic Average Shares | 91,317,142 | 88,064,482 | 90,850,040 | 89,119,344 |
| Diluted Average Shares | 91,344,584 | 102,866,858 | 103,971,546 | 102,701,707 |
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)